PCN74 COST OF IMMUNOTHERAPY TO TREAT EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)doi:10.1016/j.jval.2020.04.1576S. BilirS. OgaleValue in Health
Immune Checkpoint InhibitorsImmune checkpoint expression siteEnglish generic name for inhibitorsInhibitor trade nameThe type of tumor being treatedAdverse reactions PD-1 ICIsT cell, B cell, NK cell, Monocytes, Dendritic cell, Tumor cell Pembrolizumab Keytruda Non-small cell lung cancer, malignant melanoma...
Named for ACGT co-founder, Edward Netter, the award recognizes a researcher who has made unparalleled and groundbreaking contributions to the field of cell and gene therapy for cancer. Dr. Mackall is a leader in advancing cell and gene therapies for the treatment of solid tumors, with a major...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading ...
Based on cancer type, the lung cancer segment held the largest revenue share of 24.5% in 2022. This can largely be attributed to the rising R&D investments and introduction of new drugs for lung cancer prevention, which have increased in the past two decades. For instance, according to the...
Since the past decades, more lung cancer patients have been experiencing lasting benefits from immunotherapy. It is imperative to accurately and intelligently select appropriate patients for immunotherapy or predict the immunotherapy efficacy. In recent years, machine learning (ML)-based artificial intellige...
Regarding utilization, this issue addresses biomarker selection strategies for personalized treatment of non-small cell lung cancer (NSCLC) with immune checkpoint therapy and also the management of the unique immune response adverse events (irAEs). 展开 ...
Imfinzi (durvalumab). (2018, February). IMFINZI Is Now Approved for Unresectable Stage 3 Lung Cancer Following Chemoradiation Therapy.https://www.imfinzi.com/stage-3-nsclc.html Harris, J. (2017, July 27). Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial.https://www...
The efficacy of checkpoint inhibitor (CPI) immunotherapy in patients with non–small cell lung cancer (NSCLC) is limited by a lack of strongly predictive response markers, subjecting patients to potential underutilization of alternative effective treatments, increased risk for futile care, and unnecessar...
Oral cancer is one of the most common malignant tumors of the head and neck, not only affects the appearance, but also affects eating and even endangers life. The clinical treatments of oral cancer mainly include surgery, radiotherapy, and chemotherapy.